Table, Supplemental Digital Content 5: Baseline variables of patients with alcohol-associated hepatitis who received steroid therapy
Variables Norfloxacin (n=20) Placebo (n=13) P
Age (years) 39.85 ± 7.22 40.38 ± 10.1 0.86
Males (n, %) 20 (100%) 13 (100%) 1
BMI (kg/m2) 24.07 ± 1.97 23.86 ± 2.23 0.78
Pulse/min 82.2 ± 9.73 79.31 ± 7.83 0.37
Respiratory rate/min 19.9 ± 0.96 19.92 ± 1.38 0.95
MAP (mmHg) 87.86 ± 8.68 86.81 ± 8.46 0.73
Duration of steroid therapy (days)¶ 26.9 ± 7.68 19.36 ± 11.93 0.03
Lactulose use (n, %) 2 (10%) 1 (7.7%) 0.66
Beta-blocker therapy (n, %) 0 0
PPI use (n, %) 17 (85%) 11 (84.6%) 0.97
Ascites grade (1/2/3) (n, %) 3/10/7 2/8/3 0.75
Ascitic fluid protein < 1.5 g/dL (n, %) 10 (50%) 7 (53.8%) 0.82
Hemoglobin (g/dL) 10.62 ± 1.71 11.53 ± 1.24 0.1
Total leucocyte count (cells/L) 15,080.5 ± 8,432.4 13,821.54 ±
4,375.23 0.62
Neutrophils (%) 72.7 ± 7.5 76.23 ± 4.47 0.13
Lymphocytes (%) 18.55 ± 6.91 15.08 ± 4.46 0.12
Neutrophil-lymphocyte ratio (NLR) 4.75 ± 2.51 5.62 ± 2.1 0.31
Platelet (x 109/L) 180 ± 80.4 203 ± 90.59 0.44
INR 2.11 ± 0.48 2.41 ± 0.72 0.16
Blood urea (mg/dL) 25.35 ± 16.22 31.38 ± 18.64 0.33
Creatinine (mg/dL) 0.89 ± 0.3 1.05 ± 0.38 0.18
Sodium (mmol/L) 133.75 ± 3.11 135.31 ± 1.97 0.12
Potassium(mmol/L) 4.1 ± 0.6 4.14 ± 0.54 0.78
Total bilirubin(mg/dL) 18.25 ± 8.9 19.38 ± 10.21 0.73
Direct bilirubin (mg/dL) 10.17 ± 5.4 10.46 ± 5.51 0.88
AST (U/L) 138.05 ± 49.1 174.7 ± 71.66 0.09
ALT (U/L) 63.25 ± 24 92.85 ± 72.22 0.1
ALP (U/L) 134.4 ± 48.63 146.92 ± 42.8867 0.45
Total protein (g/dL) 6.67 ± 0.85 6.5 ±0.63 0.52
Albumin (g/dL) 2.87 ± 0.42 2.8 ± 0.5 0.62
HDL (mg/dL)* 23.66 ± 8.74 19.1 ± 5.73 0.1
Arterial lactate (mmol/L) 1.65 ± 0.55 1.7 ± 0.5 0.82
Procalcitonin (ng/ml) 0.57 ± 0.33 0.53 ± 0.44 0.74
C-reactive protein (mg/L) * 13.76 ± 13.48 10.5 ±7.84 0.43
Sepsis 3 SOFA score 3.85 ± 0.98 4.23 ± 1.36 0.36
mDF score 84.85 ± 27.32 104.67 ± 50.15 0.15
MELD NA 27.8 ± 3.79 29.62 ± 4.66 0.22
AARC score 8.15 ± 1.53 8.62 ± 1.63 0.43
AARC ACLF grade (I/II/III) 10/7/3 6/4/3 0.84
BMI-body mass index; MAP-mean arterial pressure; PPI-proton pump inhibitor; INR-international normalized ratio; AST-aspartate transaminase; ALT-alanine transaminase; ALP-alkaline phosphatase; HDL-high density lipoprotein; SOFA-sequential organ failure assessment score; mDF-modified Maddrey’s Discriminant Function score; MELD NA-model for end-stage liver disease sodium; AARC- APASL ACLF Research Consortium;
ACLF-acute-on-chronic liver failure.
¶Oral prednisolone is initiated at 40 mg/day and continued for 30 days. The drug is stopped in case of non- response (Lille’s score > 0.45 at day 7) or development of infection (at any time).
